Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia as a model of rational drug design in cancer. - Wikidata - awgldk - TriplyDB

Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia as a model of rational drug design in cancer.

Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia as a model of rational drug design in cancer.

http://www.wikidata.org/entity/Q37810070

about

Drug discovery and the use of computational approaches for infectious diseases.CEBPA-mediated upregulation of the lncRNA PLIN2 promotes the development of chronic myelogenous leukemia via the GSK3 and Wnt/β-catenin signaling pathways.Small MAF genes variants and chronic myeloid leukemia.

P2860

Q30404272-BDB6599B-1497-4430-B5D7-7501A90665C7 Q33732992-9FBB5E50-C0D5-42B3-B6A0-BA1A020C506E Q34377204-D4F96BCF-254A-4972-AA54-9F4D2203D7B7

P2860

Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia as a model of rational drug design in cancer.

http://www.wikidata.org/entity/Q37810070

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on February 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Targeting the BCR-ABL tyrosine ...... ational drug design in cancer.

@en

Targeting the BCR-ABL tyrosine ...... ational drug design in cancer.

@nl

type

label

Targeting the BCR-ABL tyrosine ...... ational drug design in cancer.

@en

Targeting the BCR-ABL tyrosine ...... ational drug design in cancer.

@nl

prefLabel

Targeting the BCR-ABL tyrosine ...... ational drug design in cancer.

@en

Targeting the BCR-ABL tyrosine ...... ational drug design in cancer.

@nl

P1433

Q37810070-3048A539-33A6-4D27-99CB-57414FC58D6A

P1476

Q37810070-D6F6BB7C-4541-45ED-8EB7-2AD048F673D2

P2093

Q37810070-B4177211-92CF-4142-911F-0E8C44C2AB44

P2860

Q37810070-05D64970-80F3-42B6-B8EA-0F847C4C753A

Q37810070-0BCC9729-D92D-437E-9298-038805C99BEB

Q37810070-10BC8813-DDD8-45E8-8CF2-1A761F060C9F

Q37810070-12029175-6E12-40D6-B761-71CC4939B64B

Q37810070-1457E458-5287-4788-B986-1F65BBDF915E

Q37810070-1495AAEC-6D76-4674-BF69-FE98D0AF73D8

Q37810070-169CF0A0-3ACD-4447-AB1E-BD4F80370C83

Q37810070-1C3F23B7-5132-4019-8FD0-581CC0C0607C

Q37810070-2E52BB34-DC86-4284-8A20-7CEAF553C6E2

Q37810070-37DC8A46-003B-44F6-9F47-46321A96D06A

P304

Q37810070-BA234B92-DC66-42E4-A591-37A98093B655

P31

Q37810070-5A7E68FF-3A15-466F-BE0D-D9DFF19A6C97

P356

Q37810070-76F658DF-D673-4540-AC6A-466C949BCCAA

P433

Q37810070-02859840-DFCA-442D-9344-D8A349191F39

P478

Q37810070-D07C27ED-A74D-42C0-ADEB-223147D4820C

P577

Q37810070-20E5E876-0CD7-4E3A-8C8C-09A0E6342AB8

P698

Q37810070-31CD1D20-56C3-4060-ABD2-1109D587C623

P921

Q37810070-587E818C-5549-4701-94D9-A742BF23CED5

Q37810070-6E4F7DF0-14F8-4424-9566-FE690F915E51

P356

P1433

Expert Review of Hematology

P1476

Targeting the BCR-ABL tyrosine ...... ational drug design in cancer.

@en

P2093

Adriana Zámečníkova

http://www.w3.org/2001/XMLSchema#string

P2860

The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study.

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.

Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial.

P304

45-56

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/EHM.09.66

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2010-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21082933

http://www.w3.org/2001/XMLSchema#string

P921

chronic myeloid leukemia